Sensei Biotherapeutics will hold a virtual KOL event on immunotherapy-resistant tumors and their treatment on October 20, 2025.
Quiver AI Summary
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company specializing in cancer therapeutics, announced a virtual key opinion leader event scheduled for October 20, 2025. This event will feature discussions by company leaders and Dr. Kyriakos Papadopoulos from START in San Antonio, focusing on the challenges and treatment options for immunotherapy-resistant solid tumors. Attendees can expect updates on the company's Phase 2 studies and data from the Phase 1/2 dose expansion cohort, particularly following an oral presentation at ESMO on October 17. Sensei's lead candidate, solnerstotug, targets the VISTA checkpoint in tumors that are resistant to PD-(L)1 therapies, aiming to enhance T cell activity in the tumor microenvironment. For registration details and more information about the company, visit their website or related social media platforms.
Potential Positives
- Announcement of a virtual key opinion leader event allows the company to engage with stakeholders and stakeholders in the cancer research community.
- Updates on Phase 2 studies and data from the Phase 1/2 dose expansion cohort could enhance investor confidence in the company's pipeline.
- Participation of Dr. Kyriakos Papadopoulos, an esteemed expert in oncology, lends credibility to the discussions and insights shared during the event.
- The focus on immunotherapy-resistant solid tumors highlights the company's commitment to addressing significant unmet medical needs in cancer treatment.
Potential Negatives
- The focus on a virtual KOL event may indicate a lack of significant data or results to share publicly, which can signal to investors and stakeholders that the company's development progress may be slower or less promising than anticipated.
- The announcement highlights the challenges of treating immunotherapy-resistant solid tumors, which could suggest that the company's product pipeline may be targeting particularly difficult scenarios, raising concerns about market viability and competition.
- The need to register for the event may limit accessibility for interested stakeholders, potentially resulting in fewer participants and diminished engagement compared to more widely available briefings or updates.
FAQ
What is the focus of Sensei Biotherapeutics?
Sensei Biotherapeutics focuses on discovering and developing next-generation therapeutics for cancer patients.
When is the virtual KOL event scheduled?
The virtual KOL event is scheduled for Monday, October 20, 2025, at 8:00 AM ET.
Who will be presenting at the KOL event?
Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START, will be presenting at the KOL event.
What is solnerstotug?
Solnerstotug is a conditionally active monoclonal antibody targeting VISTA in PD-(L)1 resistant tumors.
How can I register for the KOL event?
You can register for the KOL event by clicking the registration link provided in the press release.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNSE Hedge Fund Activity
We have seen 1 institutional investors add shares of $SNSE stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CATALIO CAPITAL MANAGEMENT, LP removed 14,719 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $126,289
- RENAISSANCE TECHNOLOGIES LLC removed 8,865 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $76,061
- BOOTHBAY FUND MANAGEMENT, LLC removed 5,433 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $46,615
- CITADEL ADVISORS LLC removed 2,886 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $22,741
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 2,395 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,872
- UBS GROUP AG removed 2,127 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $18,249
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,903 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $14,995
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SNSE Analyst Ratings
Wall Street analysts have issued reports on $SNSE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/02/2025
- Oppenheimer issued a "Outperform" rating on 03/28/2025
To track analyst ratings and price targets for $SNSE, check out Quiver Quantitative's $SNSE forecast page.
$SNSE Price Targets
Multiple analysts have issued price targets for $SNSE recently. We have seen 4 analysts offer price targets for $SNSE in the last 6 months, with a median target of $80.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $30.0 on 08/05/2025
- Francois Brisebois from Oppenheimer set a target price of $80.0 on 03/28/2025
Full Release
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current treatment landscape for immunotherapy-resistant solid tumors. To register, click here .
The event will provide an update on the Company's plans for Phase 2 studies and data from the full Phase 1/2 dose expansion cohort, including from the ESMO oral presentation on Friday, October 17th. Solnerstotug (formerly SNS-101), is a conditionally active monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation) in PD-(L)1 resistant tumors.
A live question and answer session will follow the formal presentations.
About Kyriakos Papadopoulos, MD
Kyriakos Papadopoulos, MD is the Co-Director of Clinical Research at START in San Antonio, Texas. He is board-certified in Internal Medicine, Medical Oncology & Hematology. His clinical interests include drug development and malignancies of the upper gastrointestinal-tract and lungs. Dr. Papadopoulos completed his MBBCh and MSc (Med) at the University of Witwatersrand, Johannesburg, and his specialty training in Internal Medicine at Groote Schuur Hospital, Cape Town, South Africa. He followed this with a fellowship in Medical Oncology and Hematology at the College of Physicians and Surgeons of Columbia University, NY. He served as the Florence Irving Assistant Professor of Medicine at the College of Physicians and Surgeons of Columbia University, where he was co-director of the GI and Lung Tumor Clinic. A senior clinical investigator at the Cancer Therapy & Research Center’s (CTRC) Institute for Drug Development, San Antonio, TX, he was also a member of the CTRC’s Medical Executive Committee before his departure to co-found START. He received a Career Development Award from the National Institute of Health, as well as the Anna-Maria Kellen Clinical Investigator Award of the Cancer Research Institute for immunotherapy research. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research and a Fellow of the College of Physicians of South Africa.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit
www.senseibio.com
, and follow the company on X @SenseiBio and LinkedIn.
Investor and Media Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
